Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Disease × amuvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Waldenstrom Macroglobulinemia 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Mycosis Fungoides 1 Malignant Disease 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Intraocular Lymphoma 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡